{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:13:31Z","timestamp":1788416011789,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To construct and internally validate a nomogram for predicting 60-day all-cause mortality in adult patients with\n                      <jats:italic>de novo<\/jats:italic>\n                      acute myeloid leukaemia (AML) and to compare its performance with European Leukaemia Network (ELN) 2022 risk stratification.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Clinical data from 140 patients with newly diagnosed\n                      <jats:italic>de novo<\/jats:italic>\n                      AML treated at The First Affiliated Hospital of Henan Medical University between 2020 and 2025 were retrospectively analysed. Patients were allocated by stratified random split into a training cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a098; 21 death events) and an internal validation cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a042; 8 death events). Univariate and multivariate Cox proportional hazards regression were used consistently for time-to-event analysis. Proportional hazards assumptions were assessed using Schoenfeld residuals. Collinearity diagnosis, age-stratified subgroup analysis, treatment-intensity stratification, 200 bootstrap iterations and stratified 10-fold cross-validation were performed to evaluate model stability and reduce optimism. Discrimination, calibration, clinical utility and interpretability were assessed using time-dependent area under the curve (AUC), C-index, calibration curves, decision curve analysis and Shapley Additive Explanations (SHAP) analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-nine patients (20.7%) died within 60 days. The final multivariate Cox model identified extramedullary disease (EMD) (hazard ratio [HR]=8.24, 95% confidence interval [CI]:1.91\u201335.63, P\u00a0=\u00a00.005), fibrinogen (per 100 mg\/dL: HR\u00a0=\u00a01.12, 95%CI:1.04\u20131.21, P\u00a0=\u00a00.002), ferritin (per 200 ng\/mL: HR\u00a0=\u00a01.09, 95%CI:1.02\u20131.17, P\u00a0=\u00a00.012) and number of positive prognostic genes (HR\u00a0=\u00a00.59, 95%CI:0.41\u20130.86, P\u00a0=\u00a00.006) as independent predictors. Bootstrap-corrected AUC\/C-index values were 0.88\/0.79 in the training cohort and 0.84\/0.76 in the validation cohort; stratified 10-fold cross-validation yielded an average AUC of 0.87. The nomogram outperformed ELN 2022 risk stratification alone (AUC: 0.95 vs 0.74, P&amp;lt;0.001); SHAP analysis ranked EMD as the dominant feature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This four-variable Cox nomogram showed favourable internally validated discrimination, calibration, clinical net benefit and interpretability for individualised 60-day mortality prediction in adult\n                      <jats:italic>de novo<\/jats:italic>\n                      non\u2013acute promyelocytic leukaemia AML. Multicentre prospective external validation is warranted.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1846499","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:45Z","timestamp":1788412965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a nomogram model for predicting 60-day mortality in patients with acute myeloid leukaemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Man","family":"Yang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmei","family":"Zi","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Dai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Zhu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Lv","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Lu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Leukemia","place":["Xinxiang, Henan, China"]},{"name":"Xinxiang Key Laboratory of Molecular Diagnosis and Treatment of Lymphoma","place":["Xinxiang, Henan, China"]},{"name":"The Center of Hematopoietic Stem Cell Transplantation and Immunotherapy, The First Affiliated Hospital of Henan Medical University","place":["Xinxiang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13045-021-01062-w","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12185-022-03482-x","article-title":"Very early death within 30 days after diagnosis in patients with acute myeloid leukemia","volume":"117","author":"Kusuda","year":"2022","journal-title":"Int J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaf065","article-title":"Risk of early death after acute leukemia diagnosis among adolescents and young adults","volume":"9","author":"Berkman","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.26395","article-title":"Prediction of early (4\u2010week) mortality in acute myeloid leukemia with intensive chemotherapy","volume":"97","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285805","article-title":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","volume":"110","author":"Sobas","year":"2024","journal-title":"Haematologica"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04716-4","article-title":"ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy","volume":"101","author":"Keren-Froim","year":"2022","journal-title":"Ann Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1038\/s41598-024-57295-5","article-title":"Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia","volume":"14","author":"Song","year":"2024","journal-title":"Sci Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10245768","article-title":"Redefining remission induction chemotherapy ineligibility by early mortality in de novo acute myeloid leukemia","volume":"10","author":"Li","year":"2021","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-022-01267-7","article-title":"Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations","volume":"15","author":"Eckardt","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70024","article-title":"Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta\u2010analysis","volume":"157","author":"Lin","year":"2025","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2024.02.017","article-title":"The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia","volume":"236","author":"Paterno","year":"2024","journal-title":"Thromb Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1182\/blood-2024-193182","article-title":"The association between serum ferritin and survival outcome in AML patients: a meta-analysis","volume":"144","author":"Tanariyakul","year":"2024","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027244","article-title":"Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes","volume":"145","author":"Reville","year":"2025","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2349261","DOI":"10.1177\/20406207251349261","article-title":"The clinical utility and prognostic value of next-generation sequencing for measurable residual disease assessment in acute myeloid leukemia","volume":"16","author":"Liu","year":"2025","journal-title":"Ther Adv Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1038\/s41598-025-12312-z","article-title":"Development and validation of a visual nomogram for predicting clinically significant prostate cancer in negative mpMRI using 68Ga-PSMA PET\/CT","volume":"15","author":"Hu","year":"2025","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70056","article-title":"Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development","volume":"17","author":"Ponce-Bobadilla","year":"2024","journal-title":"Clin Transl Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70024","article-title":"Prognostic impact of extramedullary disease in acute myeloid leukemia: A meta-analysis","volume":"157","author":"Lin","year":"2025","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1182\/blood-2024-202429","article-title":"Treatment intensity in acute myeloid leukemia with extramedullary disease","volume":"144","author":"Marvin-Peek","year":"2024","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.37766\/inplasy2023.10.0041","article-title":"The survival implications of extramedullary disease in acute myeloid leukemia: a systematic review and meta-analysis","author":"Liu","year":"2023"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/mbc.0000000000001172","article-title":"Disseminated intravascular coagulation in a cohort of adult acute leukemia patients: a single center experience","volume":"34","author":"Alnuaimy","year":"2023","journal-title":"Blood Coagulation Fibrinolysis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1780587","article-title":"The prognostic value of plasma fibrinogen level in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"61","author":"Zhang","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2307","article-title":"Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia","volume":"35","author":"Berger","year":"2017","journal-title":"Hematological Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125744","article-title":"Ferritin in acute myeloid leukemia: not only a marker of inflammation and iron overload, but also a regulator of cellular iron metabolism, signaling and communication","volume":"26","author":"Reikvam","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1275774","article-title":"Susceptibility of acute myeloid leukemia cells to ferroptosis and evasion strategies","volume":"10","author":"Zhang","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2024.25.8.2951","article-title":"Impact of serum ferritin and iron overload on acute myeloid leukemia outcomes: a systematic review and meta-analysis","volume":"25","author":"Sadighi","year":"2024","journal-title":"Asian Pacific J Cancer Prev APJCP"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13183","article-title":"Ferritin heavy\/light chain (FTH1\/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia","volume":"102","author":"Bertoli","year":"2018","journal-title":"Eur J Haematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s12672-025-03777-5","article-title":"Ferroptosis in AML: nanoparticles, biomarkers, and immune rewiring for therapeutic breakthroughs","volume":"16","author":"Tavakoli","year":"2025","journal-title":"Discover Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02169-y","article-title":"Ferritin-mediated mitochondrial iron homeostasis is essential for the survival of hematopoietic stem cells and leukemic stem cells","volume":"38","author":"Yi","year":"2024","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040667","article-title":"The prognostic impact of additional molecular and cytogenetic abnormalities on AML patients with NPM1- and\/or FLT3-ITD mutations receiving intensive chemotherapy: real-world data from the Greek Registry","volume":"17","author":"Lazana","year":"2025","journal-title":"Cancers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12185-023-03567-1","article-title":"Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study","volume":"118","author":"Miyashita","year":"2023","journal-title":"Int J Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280801","article-title":"The clinical impact of the molecular landscape of acute myeloid leukemia","volume":"108","author":"Kayser","year":"2023","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70132","article-title":"Age\u2010stratified machine learning identifies divergent prognostic significance of molecular alterations in AML","volume":"9","author":"Eckardt","year":"2025","journal-title":"HemaSphere"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011103","article-title":"Genetic identification of AML patients older than 60 years achieving long-term survival with intensive chemotherapy","volume":"138","author":"Itzykson","year":"2021","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1558496","article-title":"Integrated multiomics analysis and machine learning refine neutrophil extracellular trap-related molecular subtypes and prognostic models for acute myeloid leukemia","volume":"16","author":"Zhong","year":"2025","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06248-7","article-title":"Prediction of survival in acute myeloid leukemia patients by extracellular to intracellular water ratio and sarcopenia: development and validation of a novel nomogram","volume":"104","author":"Fang","year":"2025","journal-title":"Ann Hematol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17874","DOI":"10.1038\/s41598-024-68755-3","article-title":"Machine learning-based biomarker screening for acute myeloid leukemia prognosis and therapy from diverse cell-death patterns","volume":"14","author":"Qin","year":"2024","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.19513","article-title":"Development and validation of an in-hospital major adverse cardiovascular events risk model for young patients with acute coronary syndrome: a retrospective cohort study","volume":"13","author":"Zheng","year":"2025","journal-title":"PeerJ"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41598-025-85310-w","article-title":"Prediction model establishment of prognosis factors for acute myeloid leukemia based on the SEER database","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846499\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:22:47Z","timestamp":1788412967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846499\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":40,"alternative-id":["10.3389\/fonc.2026.1846499"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1846499","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1846499"}}